Information Provided By: 
Fly News Breaks for September 5, 2019
ORTX
Sep 5, 2019 | 07:25 EDT
Barclays analyst Gena Wang started Orchard Therapeutics with an Overweight rating and $21 price target. The company's lentiviral gene therapy platform strategically targets genetic diseases that have validated approaches with hematopoietic stem cell transplant, Wang tells investors in a research note. She believes Orchard's three lead assets are "fairly de-risked" with high likelihood of regulatory approvals in 2020 and 2021. Multiple near- and mid-term catalysts make for a favorable risk/reward on the shares, says the analyst.
News For ORTX From the Last 2 Days
There are no results for your query ORTX
